Abcam, ab314888, Anti-IL22 RA2/IL-22BP antibody [EPR25046-231] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal IL22 RA2/IL-22BP antibody. Carrier free. Suitable for WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR25046-231,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab314888 is the carrier-free version of
ab314887
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
IL22 RA2 also known as IL-22BP (IL-22 binding protein) acts as a soluble decoy receptor for IL-22 and it plays a role in modulating IL-22 activity. IL-22 promotes the survival and innate immunity of epithelial cells. IL22 RA2 binds IL-22 with high affinity preventing it from interacting with its membrane receptor IL22R1. This protein is approximately 27 kDa in size and is expressed mainly in the placenta spleen and skin. IL22 RA2 does not get anchored to the cell membrane which allows it to regulate IL-22 activity distantly from the site of its production.
Biological function summary
IL22 RA2 is involved in dampening the pro-inflammatory effects of IL-22. IL-22 is part of the interleukin-10 (IL-10) cytokine family and IL22 RA2 adjusts the balance of IL-22 activity within tissue microenvironments. By neutralizing IL-22 IL22 RA2 reduces cytokine signaling that would lead to excessive inflammation. Though it does not form part of a larger receptor complex on the cell surface its role is significant in controlling the spread of IL-22 mediated signals in tissues prone to inflammation.
Pathways
IL22 RA2 influences the IL-22/STAT3 signaling pathway which is central in managing inflammatory responses and maintaining epithelial barrier functions. IL22 RA2 inhibits IL-22 induced STAT3 phosphorylation effectively blocking downstream pathway activation. Another related protein in this signaling route is IL22R1 which when not bound by IL22 RA2 forms a receptor complex with IL10R2 to mediate the effects of IL-22 in target tissues.
IL22 RA2 has been linked to inflammatory bowel disease (IBD) and psoriasis. These conditions show deregulation of IL-22 activity where IL22 RA2 plays a role in modulating the inflammatory environment. By binding IL-22 IL22 RA2 affects the IL-22/IL22R1 axis reducing exacerbation of chronic inflammation seen in these diseases. Understanding its interaction with IL-22 can aid in the development of targeted therapies for managing inflammation in conditions such as IBD and psoriasis.